Current use of Antifungal Eye Drops and How to Improve Therapeutic Aspects in Keratomycosis
|Anxo Fernández-Ferreiro1,2,5*, Miguel González-Barcia1,5, Gil Martínez M3, Blanco Méndez J2, FJ Otero-Espinar2, F Ferreiro A4, Victoria Díaz Tome2 and MJ Lamas1,5|
|1Pharmacy Department, Xerencia de Xestión Integrada de Santiago de Compostela, (SERGAS), Spain|
|2Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Spain|
|3Ophthalmology Department, Hospital de Conxo, Xerencia de Xestión Integrada de Santiago de Compostela, (SERGAS), Spain|
|4Clinical Analysis Department, Hospital Universitario Nuestra Señora de la Candelaria , Spain|
|5Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS-ISCIII), Spain|
|Corresponding Author :||Anxo Fernández-Ferreiro
Xerencia de Xestión Integrada de Santiago de Compostela
(SERGAS), Travesía Choupana s/n,Santiago de Compostela
E-mail: [email protected]
|Received: September 30, 2015; Accepted: January 19, 2016; Published: January 25, 2016|
|Citation: Ferreiro AF, Barcia MG, Martínez MG, Méndez JB, Espinar FJO, et al. (2016) Current use of Antifungal Eye Drops and How to Improve Therapeutic Aspects in Keratomycosis. Fungal Genom Biol 6:130. doi:10.4172/2165-8056.1000130|
|Copyright: © 2016 Ferreiro AF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: Fungal keratitis is a disease that has a low prevalence and poor outcome because of its minimal therapeutic spectrum.
Objective: The purpose of the current study is to provide an overview of the use of antifungal topical eye drops in a third level hospital and to highlight possible improvements that can optimize their therapeutic use.
Methods: Fungal keratitis cases treated in the Ophthalmology Department of a Tertiary hospital were reviewed in a four-year retrospective study.
Results: For four years, 24 patients received an antifungal eye drop treatment for fungal keratitis: 20% were treated with topical fluconazole and 80% were treated with topical voriconazole (79% in monotherapy and 21% in conjunction with topical natamycin). In most cases, fungal growth was been detected and susceptibility was rarely reported, facilitating the realization of directed treatment towards the most frequently isolated fungi (Fusarium, Candida, Paecilomyces).
Conclusion: In a disease with low prevalence and complicated management, we have detected improvement in the three involved departments: ophthalmology, pharmacy and microbiology.